Medtronic (NYSE: MDT) reported Q2 EPS of $1.36, $0.05 better than the analyst estimate of $1.31. Revenue for the quarter came in at $9 billion versus the consensus estimate of $8.87 billion.

GUIDANCE:

Medtronic sees FY2026 EPS of $5.62-$5.66, versus the consensus of $5.62.

For earnings history and earnings-related data on Medtronic (MDT) click here.